Suggested Remit: To appraise the clinical and cost effectiveness of semaglutide, within its marketing authorisation, in addition to a reduced calorie diet and increased physical activity, for the management of people with obesity or overweight with risk factors.
Status In progress
Decision Selected
Process STA 2018
ID number 3850

Project Team

Project lead Thomas Feist

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Novo Nordisk
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Obesity UK
  The UK Obesity Organisation
Professional groups British Dietetic Association
  British Obesity and Metabolic Surgery Society (BOMSS)
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies GlaxoSmithKline
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee


Key events during the development of the guidance:

Date Update
17 June 2022 - 01 July 2022 Final draft guidance
17 June 2022 The final appraisal document (FAD) has now been issued. Please note that this product is not yet launched in England and Wales. NICE will only be able to issue final technology appraisal guidance once it has launched and the list price is available. An expected final guidance publication date will be added to this page when we have more information.
15 March 2022 Committee meeting: 2
08 February 2022 - 01 March 2022 Draft guidance
18 January 2022 Committee meeting: 1
17 May 2021 Invitation to participate
05 March 2021 In progress. Topic is now in progress
25 November 2020 - 23 December 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual